medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2014; 13 (2)


Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports

Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, Chirino RA, Dávalos M, Méndez-Sánchez N, Arrese M, Schinoni M, Lucena MI, Andrade RJ

Idioma: Ingles.
Referencias bibliográficas: 48
Paginas: 231-239
Archivo PDF: 112.36 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ostapowicz G, Fontana R, Schiedt F, Larson A, Davern T, Han S, McCashland T, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-54.

  2. Fontana RJ, Seeff LB, Andrade RJ, Björnsson E, Day CP, Serrano J, Hoofnagle JH. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52: 730-42.

  3. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42: 481-9.

  4. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García Muñoz B, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.

  5. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.

  6. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89: 806-15.

  7. Restrepo JC, Muñoz JF, Correa G, Zuleta J, Londoño M, Botero A, Osorio G, et al. Hepatotoxicidad detectada en un hospital de cuarto nivel en la ciudad de Medellín. Acta Med Colomb 2008; 33: 261-7.

  8. WHO Collaborating Center for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2013. Oslo, 2012.

  9. Bessone F, Colombato L, Fassio E, Reggiardo M, Vorobioff J, Tanno H. The spectrum of nimesulide induce hepatotoxicity. An overview. Antiinflamm Antiallergy Agents Med Chem 2010; 9: 355-65.

  10. Grignola JC, Arias L, Rondan M, Solá L, Bagnulo H. Hepatotoxicidad asociada a la nimesulida. Revisión de 5 casos. Arch Med Int 1998; XX: 13-18.

  11. Bessone F, Colombato L, Frider B, Tsariktsian G, Bruguera M, Cohen H, Hernández N, et al. Ciproterone inducedliver– injury includes autoimmune-hepatitis and a spectrum of varying severity of acute hepatocellular damage. Basic Clin Pharmacol Toxicol 2011; 109: 32-40.

  12. Bermúdez J, Brahm M, Poniachik J, Contreras J, Valera J, Smok G, Brahm J. Espectro clínico de la hepatotoxicidad por nitrofurantoína en una serie clínica de 12 pacientes. Gastroenterol Latinoam 2012; 23: 129-33.

  13. Contreras J, Poniachik J, Planzer M, Lazarte R, Smok G, Oksenberg D, Madrid A, et al. Daño hepático por fármacos: características clínicas e histológicas en 33 casos. Rev Med Chile 2003; 131: 1128-34.

  14. Zapata R, Sanhueza E, Gómez F, Contreras J, Uribe M, Humeres R, Martinez W, et al. Falla hepática fulminante en adultos. Etiología, pronóstico y evolución de pacientes evaluados en dos unidades de trasplante hepático en Chile durante una década. Gastroenterología Latinoamericana 2012; 23(S4): (abstract).

  15. García del Risco F, Camargo JM, Arrieta HE. Hepatitis colestásica inducida por flutamida. Presentación de un caso. Rev Col Gastroenterol 2009; 24: 408-12.

  16. Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, Buckel E, et al. Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann Hepatol 2011; 10: 93-8.

  17. Pereira R, Tresoldi A, Hessel G. Insuficiência Hepática pelo uso de isoniazida. Relato de caso. Arq Gastroenterol 2000; 37: 72-5.

  18. Reto L, Castillo J, Pichilingue P, Pichilingue O. Hepatotoxicidad por fármacos antituberculosos en pediatría. Rev Gastroenterol Peru 2005; 25: 362-5.

  19. Gonzalez O, Arpa A, Peñaranda O, Montero T, Perez M, Perez F. Reacción idiosincrásica fatal al propiltiouracilo. Disponible en: [http://bvs.sld.cu/revistas/mil/vol37_4_08/ mil12408.htm] [19/09/2011].

  20. Poniachik J, Guerrero J, Calderon P, Smok H, Morales A, Munoz G, Venegas M. Hepatitis colestasica por piroxicam: caso clínico. Rev Med Chile 1998; 126: 548-52.

  21. Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol 2010; 16: 5651-61.

  22. Gutiérrez M. Falla hepática por halotano-reporte de un caso. Rev Col Anestesiol 2001; 2: 163-5.

  23. Antoniuk S, Bruck I, Honnicke LR, Flenik L, Barreiro J, Cat R. Insuficiencia aguda hepatica associada ao acido valproico na infancia. Arq Neuropsiquiatr 1996; 54: 652-4.

  24. Soza A, Riquelme F, Alvarez M, Duarte I, Glasinovic J, Arrese M. Hepatotoxicidad por amoxicilina/ácido clavulánico: caso clínico. Rev Med Chile 1999; 127: 1487-91.

  25. Castro MG, Molina A, Martínez JM, Gallardo V, Liceaga M. Hepatotoxicidad por amoxicilina-clavulanato y revisión de la bibliografía. Med Int Mex 2011; 27: 406-10.

  26. Cocozzella D, Curciarello J, Corallini O, Olivera A, Alburquerque MM, Fraquelli E, Zamagna L. Propafenone hepatotoxicity Report of two new cases. Dig Dis Sci 2003; 48: 354-7.

  27. Zapata A, Casillas A, Bosques F. Terbinafine hepatotoxicity. A case report and review of literature. Ann Hepatol 2003; 2: 47-51.

  28. Burstein Z, Vildósola H, Lozano Z, Verona R, Vargas G. Hepatitis tóxica colestásica por terbinafina: reporte de caso. Rev Gastroenterol Peru 2004; 24: 357-62.

  29. Ridruejo E, Cacchione R, Villamil A, Marciano S, Gadano A, Mandó O. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007; 13: 6608-11.

  30. Días J, Dávalos M, Roman R, Bustios C, Zumaeta E. Hepatotoxicidad y pancreatitis por sales de oro: reporte de caso. Rev Gastroenterol Peru 2004; 24: 353-6.

  31. Romero J, Carreiro M, Hinesfrosa H, Leon R, Cifuentes C, Longart L, Roa J, et al. Insuficiencia hepática fulminante secundaria a trovafloxacina: reporte de un caso. GEN 2000; 54: 287-91.

  32. Soza A, Larrain S. Hepatotoxicidad por verapamil. Reporte de un caso. Gastroenterol Latinoam 2010; 21: 27-9.

  33. Castaño G, Etchart C, Sookoian S. Vitamin A toxicity in a physical culturist patient: a case report and review of the literature. Ann Hepatol 2006; 5: 293-5.

  34. Vasco M, Rui V. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26: 664-9.

  35. Danan G, Benichou C. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.

  36. Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guillemet C, Lenoir C, et al. Incidence of drug induced hepatic injuries. A French population-based study. Hepatology 2002; 36: 451–5.

  37. Björnsson E, Bergmann O, Björnsson E, Kvaran R, Olafsson S. Incidence, presentation, and outcomes in patients with drug induced liver Injury in the general population in Iceland. Gastroenterology 2013; 144: 1419-25.

  38. de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004; 58: 71-80.

  39. Hernández N, Sánchez A, di Pace M, Bessone F, Arrese M, Brahm J, et al. Espectro de la hepatotoxicidad en Latinoamérica: fundación y resultados iniciales del registro español- latinoamericano de hepatotoxicidad. Gastroenterol Hepatol 2013; 36: 85 (abstract).

  40. Suzuki A, Andrade R, Björnsson E, Lucena M, Lee W, Yuen N, Hunt C, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in Vigi- BaseTM unified list based on international collaborative work. Drug Saf 2010; 33: 503-22.

  41. Reuben A, Koch D, Lee W, and the Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76.

  42. Lucena MI, Cohen H, Hernández N, Bessone F, Dacoll C, Stephens C, Borraz Y, et al. Hepatotoxicidad, un problema global con especificidades locales: hacia la creación de una Red Hispano Latinoamericana de Hepatotoxicidad. Gastroenterol Hepatol 2011; 34: 361-8.

  43. ANMAT suspende la comercialización de la droga nimesulida. Boletín para profesionales 2009: XVII(3): 17-24.

  44. Agarwal V, Mc Hutchinson J, Hoofnagle J. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 2008: 463-70.

  45. Mindikouglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the Unitred States: analysis of the united network for organ sharing database. Liver Transplantation 2009; 15: 719-29.

  46. Andrade RJ, Robles M, Lucena MI. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf 2009; 8: 709-14.

  47. García-Cortés M, Stephens C, Lucena MI, Fernández- Castañer A, Andrade RJ, Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos GEHAM). Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011; 55: 683-91.

  48. Bessone F, Hernández N, Dávalos M, Parana R, Schinoni M, Lizarzabal M, Kershenobich D, et al. Building a Spanish Latin - American network on drug induced liver injury: much to get from a joint collaborative initiative. Ann Hepatol 2012; 11: 544-9.




2020     |     www.medigraphic.com